<DOC>
	<DOCNO>NCT00911443</DOCNO>
	<brief_summary>The purpose study test safety efficacy different dos thymosin alpha 1 ( 1.6 mg , 3.2 mg , 6.4 mg ) combination dacarbazine without Interferon alpha treat patient affected stage IV melanoma . Primary end-point Tumor Response evaluate accord Response Evaluation Criteria In Solid Tumors ( RECIST ) . Secondary end-points Overall Survival Progression Free Survival . Ninety-five patient allocate arm test hypothesis P0 &lt; = 0.05 v alternative hypothesis P1 &gt; = 0.15 ( alpha = 5 % , within-group statistical analysis beta = 95 % ) .</brief_summary>
	<brief_title>Thymosin Alpha 1 , Interferon Alpha , Both , Combination With Dacarbazine Patients With Malignant Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Thymalfasin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Have read sign informed consent form 18 year &lt; =Age &lt; = 75 year Adequate contraception practice ( fertile female patient ) Confirmed diagnosis metastatic melanoma ( stage IV ) unresectable metastasis &gt; = 1 measurable lesion Adequate renal function demonstrate serum creatinine level &lt; 1.5 mg/deciliter ( dl ) Absolute Neutrophil Count ( ANC ) &gt; = 1.5 x 10000000000/L ; platelet &gt; = 100 x 10000000000/Liter ( L ) Good performance status : PS &lt; = 1 ( ZUBRODECOGWHO scale ) At least 12 week life expectancy Clinical diagnosis autoimmune disease Transplant recipient Pregnancy document urine pregnancy test lactation Previous treatment thymosin alpha 1 Previous treatment chemotherapy Presence Central Nervous System ( CNS ) metastases Concomitant prior history malignancy melanoma Participation another investigational trial within 30 day study entry Active infectious process selflimiting nature</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>